LT2939025T - Ląstelinio imuninio atsako tyrimo būdas - Google Patents

Ląstelinio imuninio atsako tyrimo būdas

Info

Publication number
LT2939025T
LT2939025T LTEP13869475.7T LT13869475T LT2939025T LT 2939025 T LT2939025 T LT 2939025T LT 13869475 T LT13869475 T LT 13869475T LT 2939025 T LT2939025 T LT 2939025T
Authority
LT
Lithuania
Prior art keywords
immune response
cell mediated
mediated immune
response assay
assay
Prior art date
Application number
LTEP13869475.7T
Other languages
English (en)
Inventor
Jeff Boyle
Ashley KNIGHTS
Carmen MUNIAN
Original Assignee
Cellestis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51019570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2939025(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellestis Limited filed Critical Cellestis Limited
Publication of LT2939025T publication Critical patent/LT2939025T/lt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/34Sugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/555Interferons [IFN]
    • G01N2333/57IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP13869475.7T 2012-12-28 2013-12-20 Ląstelinio imuninio atsako tyrimo būdas LT2939025T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746965P 2012-12-28 2012-12-28
EP13167355 2013-05-10
PCT/AU2013/001509 WO2014100853A1 (en) 2012-12-28 2013-12-20 A cell mediated immune response assay

Publications (1)

Publication Number Publication Date
LT2939025T true LT2939025T (lt) 2018-08-10

Family

ID=51019570

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13869475.7T LT2939025T (lt) 2012-12-28 2013-12-20 Ląstelinio imuninio atsako tyrimo būdas

Country Status (15)

Country Link
US (3) US10564150B2 (lt)
EP (4) EP3745128B1 (lt)
JP (5) JP6431484B2 (lt)
CN (2) CN105051537B (lt)
AU (3) AU2013370928B2 (lt)
CY (1) CY1123265T1 (lt)
DK (2) DK3421997T3 (lt)
ES (2) ES3031233T3 (lt)
HU (2) HUE072727T2 (lt)
LT (1) LT2939025T (lt)
PL (1) PL3745128T3 (lt)
PT (1) PT2939025T (lt)
SI (2) SI2939025T1 (lt)
TR (1) TR201809679T4 (lt)
WO (2) WO2014100860A2 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2939025T1 (sl) 2012-12-28 2018-09-28 Cellestis Limited Preizkus celično posredovanega imunskega odziva
WO2016065199A1 (en) * 2014-10-23 2016-04-28 Qiagen Sciences, Llc Peptide composition and uses thereof
GB201605210D0 (en) 2016-03-29 2016-05-11 Oxford Immunotec Ltd Assay
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
WO2018213192A1 (en) * 2017-05-15 2018-11-22 University Of Miami Materials and methods for subjects at risk for viral reactivation
JP7320645B1 (ja) 2022-04-13 2023-08-03 株式会社アマダ プレスブレーキ、及びプレスブレーキのテーブル駆動方法
EP4728275A1 (en) * 2023-06-19 2026-04-22 Immune Functional Diagnostics, LLC Methods and assays for immune phenotyping

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US434010A (en) * 1890-08-12 Band-saw guide
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
EP0014050A3 (en) 1979-01-16 1980-10-01 Beecham Group Plc Interferon production
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
JP3187622B2 (ja) * 1993-10-07 2001-07-11 カネボウ株式会社 リポソーム
IL121116A (en) * 1997-06-19 2000-12-06 Savyon Diagnostics Ltd Stabilization of polypeptides for use in immunoassay procedures
IL141868A0 (en) * 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
CN1262131A (zh) 1999-01-29 2000-08-09 长春长生实业股份有限公司 海藻糖替代人血白蛋白保护微生物及微生物制剂
DE60040727D1 (de) 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DE10031236A1 (de) 2000-06-27 2002-01-10 Qiagen Gmbh Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien
JP4231688B2 (ja) * 2000-08-16 2009-03-04 タカラバイオ株式会社 抗原特異的細胞傷害性t細胞拡大培養方法
JPWO2002038146A1 (ja) * 2000-11-07 2004-03-11 株式会社林原生物化学研究所 粘膜免疫調節剤並びにその用途
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
DE60234015D1 (de) * 2001-01-08 2009-11-26 Us Gov Health & Human Serv Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
ES2310201T3 (es) * 2001-02-13 2009-01-01 Government Of The United States Of America, As Represented By The Secretary Of The Army Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
US7258837B2 (en) * 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US7257086B2 (en) * 2002-08-27 2007-08-14 Terabeam Corporation Method and system for effectuating network routing over primary and backup channels
AU2002952548A0 (en) * 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
JP3675800B2 (ja) * 2003-03-31 2005-07-27 株式会社東芝 音声通話ソフトウェア、及び音声通話装置
WO2004099771A1 (en) 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
EP1529536A1 (en) * 2003-11-05 2005-05-11 Institut Pasteur Immunogenic composition having improved immunostimulation capacity
AU2005250055B2 (en) 2004-06-02 2008-09-11 Adalta Pty Ltd Binding moieties based on shark IgNAR domains
BRPI0616879A2 (pt) * 2005-10-04 2011-07-05 Alk Abello As formulação de vacina sólida
EP1933867A1 (en) * 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
KR100784485B1 (ko) 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
EP2080024B1 (en) 2006-10-16 2010-10-06 Thijsen, Steven Frederik Theodoor Cross-spot
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
CN101711360A (zh) 2007-03-16 2010-05-19 赛乐思迪斯有限公司 细胞介导的免疫应答检验及其试剂盒
US20100317084A1 (en) 2007-05-10 2010-12-16 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
CA2695421A1 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
GB0716070D0 (en) 2007-08-17 2007-09-26 Fusion Antibodies Ltd Diagnostic method and kit
EP2106803A1 (en) 2008-04-04 2009-10-07 Fondazione Centro San Raffaele del Monte Tabor Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
EP2281200A4 (en) 2008-04-23 2011-07-06 Healthlinx Ltd TEST PROCEDURE FOR DETECTING A GYNECOLOGICAL SUFFERING
CN102105786B (zh) * 2008-07-25 2014-10-29 赛乐思迪斯有限公司 诊断方法
US20110131720A1 (en) * 2009-12-09 2011-06-09 David Franklin Dean Wall Mounted Lift Chair
CN102713619B (zh) 2009-12-23 2018-08-10 塞尔雷斯蒂斯有限公司 测量细胞介导免疫反应的试验
JP5630637B2 (ja) * 2010-02-26 2014-11-26 日立化成株式会社 感光性樹脂組成物
AU2011244348B2 (en) * 2010-04-20 2015-02-12 Octapharma Ag New stabilizing agent for pharmaceutical proteins
US10578612B2 (en) 2010-05-28 2020-03-03 Cellestis International Pty Ltd. Diagnostic assay
US20140087363A1 (en) * 2010-12-09 2014-03-27 Hvidovre Hospital Method for generating, storing, transporting, eluting and detecting clinical relevant information in plasma using filter paper
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US20140127260A1 (en) * 2011-06-24 2014-05-08 Ramesh V. Chintala Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CA2840484C (en) * 2011-06-29 2020-04-14 Cellestis Limited A cell mediated immune response assay with enhanced sensitivity
EP2690839B1 (en) 2012-07-23 2018-09-26 STMicroelectronics (Rousset) SAS NFC apparatus capable to perform a contactless tag reading function
WO2014085713A1 (en) 2012-11-30 2014-06-05 The Methodist Hospital Research Institute Methods and compositions for detecting tuberculosis
SI2939025T1 (sl) * 2012-12-28 2018-09-28 Cellestis Limited Preizkus celično posredovanega imunskega odziva
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha

Also Published As

Publication number Publication date
EP3421997B1 (en) 2020-06-17
EP3421997A1 (en) 2019-01-02
PL3745128T3 (pl) 2025-09-22
EP4582807A3 (en) 2025-10-15
US20250369957A1 (en) 2025-12-04
EP2939025A1 (en) 2015-11-04
JP6431484B2 (ja) 2018-11-28
TR201809679T4 (tr) 2018-07-23
CN110118871A (zh) 2019-08-13
HUE072727T2 (hu) 2025-12-28
WO2014100860A2 (en) 2014-07-03
JP2022066193A (ja) 2022-04-28
AU2013370928A1 (en) 2015-07-30
US10564150B2 (en) 2020-02-18
DK2939025T3 (en) 2018-08-06
CY1123265T1 (el) 2021-12-31
EP3745128C0 (en) 2025-05-21
AU2019204756A1 (en) 2019-07-18
AU2021203579A1 (en) 2021-07-01
WO2014100853A1 (en) 2014-07-03
AU2019204756B2 (en) 2021-05-20
JP2023126213A (ja) 2023-09-07
DK3421997T3 (da) 2020-09-14
EP3745128B1 (en) 2025-05-21
EP4582807A2 (en) 2025-07-09
CN105051537A (zh) 2015-11-11
JP2019013254A (ja) 2019-01-31
JP7008739B2 (ja) 2022-01-25
EP2939025A4 (en) 2016-04-20
ES3031233T3 (en) 2025-07-07
CN105051537B (zh) 2019-04-12
ES2677723T3 (es) 2018-08-06
JP2020115870A (ja) 2020-08-06
JP2016504036A (ja) 2016-02-12
AU2013370928B2 (en) 2019-05-02
SI2939025T1 (sl) 2018-09-28
EP3745128A1 (en) 2020-12-02
PT2939025T (pt) 2018-07-31
US20200141927A1 (en) 2020-05-07
SI3421997T1 (sl) 2020-10-30
US20150330972A1 (en) 2015-11-19
US12153042B2 (en) 2024-11-26
JP7826248B2 (ja) 2026-03-09
HUE038527T2 (hu) 2018-10-29
EP2939025B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
ZA201309155B (en) A cell mediated immune response assay with enhanced sensitivity
SG11201408585YA (en) Separator
GB201203938D0 (en) Assay system
SI3421997T1 (sl) Test celično posredovanega imunskega odziva
GB201221341D0 (en) Pallets
GB201220662D0 (en) Assays
EP2913457A4 (en) TILE CUTTER
GB201212528D0 (en) Assay
GB201212550D0 (en) B cell assay
GB201209664D0 (en) Assay device
PL2836834T3 (pl) Znacznik analityczny
HUE050539T2 (hu) Sejtközvetített immunválasz esszé
PT2903902T (pt) Estrado ecológico
GB201219024D0 (en) Assay
GB201213229D0 (en) Assay
GB201212778D0 (en) Assay
GB201416623D0 (en) Cell migration assay
AP00418S1 (en) Assay devices
GB201220025D0 (en) Structural element
GB201202633D0 (en) A cell
GB201214030D0 (en) Concept six
PH32012001058S1 (en) Pallet
GB201203439D0 (en) Pallet
GB201204763D0 (en) Puilse lazer
GB201201916D0 (en) Plat up